DPP-4 Therapy Center

Five-year study challenges alleged increase in risk for severe muscular injury when combining DPP-4 inhibitors with lipid-lowering agents.

Diabetes management can be a major factor in renal transplant aftercare; can DPP-4 therapy help improve outcomes?

Patients taking the DPP-4 inhibitor sitagliptin had lower risk of needing intensive care or needing mechanical ventilation. 

Dual and triple therapy just got a little easier.

Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.

A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.

Research into the interaction of DPP4 and coronavirus may be a step toward a cure. 

The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.  

More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.

The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.